First-line use of encorafenib and binimetinib in BRAF V600E NSCLC recorded a median overall survival of 47.6 months, according to data presented at the ESMO congress.
|  Read More  JPost.com – The Jerusalem Post – All News from the Middle East, Israel, and the Jewish World